Head to Head Review: Accelerate Diagnostics (AXDX) vs. Presbia (LENS)

Accelerate Diagnostics (NASDAQ: AXDX) and Presbia (NASDAQ:LENS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation and dividends.

Insider & Institutional Ownership

47.9% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 16.1% of Presbia shares are held by institutional investors. 50.0% of Accelerate Diagnostics shares are held by company insiders. Comparatively, 74.7% of Presbia shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Accelerate Diagnostics and Presbia’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Accelerate Diagnostics -3,085.36% -60.99% -57.85%
Presbia N/A -173.64% -137.41%

Volatility and Risk

Accelerate Diagnostics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Presbia has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500.

Earnings & Valuation

This table compares Accelerate Diagnostics and Presbia’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Accelerate Diagnostics $250,000.00 6,315.60 -$66.37 million ($1.20) -23.75
Presbia $10,000.00 5,872.16 -$15.75 million ($1.20) -2.86

Presbia has lower revenue, but higher earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Presbia, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Accelerate Diagnostics and Presbia, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accelerate Diagnostics 0 1 1 0 2.50
Presbia 0 0 3 0 3.00

Accelerate Diagnostics currently has a consensus price target of $33.00, suggesting a potential upside of 15.79%. Presbia has a consensus price target of $9.67, suggesting a potential upside of 181.83%. Given Presbia’s stronger consensus rating and higher possible upside, analysts clearly believe Presbia is more favorable than Accelerate Diagnostics.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

About Presbia

Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. The Company’s lens, referred to as the microlens, is a miniature lens designed to be surgically implanted in a patient’s eye to improve that patient’s ability to see objects at close distances. The microlens is a disc shaped lens that has a refractive zone in the periphery designed to improve near vision problems associated with presbyopia and a central zone that is designed to improve distance vision. The Company’s solution is a standalone solution for plano presbyopes, or those individuals suffering from presbyopia but do not have any other visual disorders.

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply